TRIO Pharmaceuticals, Inc. is a cancer immunotherapeutics company pioneering dual action drugs to generate immunogenic tumors. TRIO's innovative antibody drugs directly stop tumor growth and selectively stop immunosuppression in the tumor without targeting the current immune checkpoint pathways.
Location: United States
Employees: 1-10
Total raised: $3.1M
Founded date: 2018
Investors 3
| Date | Name | Website |
| - | Myeloma In... | myelomainv... |
| 03.12.2022 | SeedFolio | seedfolio.... |
| 12.08.2021 | MBC BioLab... | mbcbiolabs... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 03.12.2024 | - | $3.1M | - |
Mentions in press and media 4
| Date | Title | Description |
| 03.12.2024 | TRIO Pharmaceuticals Completes $3.1M Financing Round | TRIO Pharmaceuticals, a San Diego, CA-based biotechnology company pioneering bispecific antibodies for the treatment of cancer, raised $3.1M in funding. The round was led by Friedman Bioventure Fund (FBVF). Othe investors included Multiple ... |
| 03.12.2024 | TRIO Pharmaceuticals Closes $3.1M Financing | SAN DIEGO, CA, TRIO Pharmaceuticals announced the successful completion of a $3.1 million financing round. >> Click here for more funding data on TRIO Pharmaceuticals >> To export TRIO Pharmaceuticals funding data to PDF and Ex... |
| - | Trio Pharmaceuticals | “TRIO pharmaceuticals is developing novel dual targeting antibody drugs to treat cancer by reducing toxicity and increasing immune response to fight against cancer more effectively.” |
| - | Trio Pharmaceuticals | “TRIO Pharmaceuticals, Inc.” |